Harbor Capital Advisors Inc. Has $845,000 Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Harbor Capital Advisors Inc. reduced its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 24.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,878 shares of the company's stock after selling 10,109 shares during the period. Harbor Capital Advisors Inc.'s holdings in Kymera Therapeutics were worth $845,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in KYMR. Price T Rowe Associates Inc. MD raised its holdings in shares of Kymera Therapeutics by 3.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,870,333 shares of the company's stock worth $276,395,000 after purchasing an additional 224,859 shares in the last quarter. Wellington Management Group LLP grew its position in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company's stock worth $213,514,000 after buying an additional 688,967 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in shares of Kymera Therapeutics by 14.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after buying an additional 650,000 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Kymera Therapeutics by 2.8% in the fourth quarter. Vanguard Group Inc. now owns 4,887,312 shares of the company's stock valued at $196,617,000 after buying an additional 133,546 shares in the last quarter. Finally, Driehaus Capital Management LLC lifted its position in shares of Kymera Therapeutics by 4.6% during the 4th quarter. Driehaus Capital Management LLC now owns 1,390,372 shares of the company's stock valued at $55,935,000 after acquiring an additional 61,669 shares during the last quarter.

Kymera Therapeutics Price Performance

KYMR traded down $0.49 during trading on Tuesday, reaching $46.35. 551,455 shares of the stock traded hands, compared to its average volume of 615,833. The stock's 50-day simple moving average is $33.68 and its two-hundred day simple moving average is $35.78. Kymera Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $53.27. The stock has a market cap of $3.02 billion, a price-to-earnings ratio of -14.95 and a beta of 2.07.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The firm's revenue was up 114.6% on a year-over-year basis. During the same period in the previous year, the company earned ($0.69) EPS. Research analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of the stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total value of $1,470,000.00. Following the transaction, the chief executive officer now directly owns 660,482 shares in the company, valued at approximately $32,363,618. This represents a 4.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 over the last ninety days. 16.01% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KYMR. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Morgan Stanley upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $49.00 to $79.00 in a report on Tuesday, June 3rd. JPMorgan Chase & Co. raised their price objective on shares of Kymera Therapeutics from $57.00 to $64.00 and gave the stock an "overweight" rating in a research note on Tuesday, June 3rd. Finally, UBS Group lowered their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Two investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $59.82.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.